Repetitive transcranial magnetic stimulation is now available in 7 of 10 Canadian provinces,
having gained Health Canada approval in 2002. Clinics accept referral in at least 13 major …

Background: Repetitive transcranial magnetic stimulation (rTMS) has shown safety and
efficacy for treatment‐resistant depression, but requires daily treatment for 4–6 weeks …

Background To date, several randomized controlled trials (RCTs) have shown the efficacy of
repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depression …

Repetitive transcranial magnetic stimulation (rTMS) has been investigated as treatment for
major depressive episodes since the early 1990s. Using data from a recent meta-analysis …

Repetitive transcranial magnetic stimulation (rTMS) is a noninvasive somatic treatment with
promising therapeutic potential for a variety of neuropsychiatric conditions (George & …

Major depressive disorder (MDD) is common and highly disabling. In the United States, the
estimated 12-month prevalence of MDD is 8.9 million adults, of which one third (2.76 million) …

Objective: To examine issues relating to the potential introduction of repetitive transcranial
magnetic stimulation (rTMS) into clinical practice as a treatment for depression. Method: A …

Background Evaluation of repetitive transcranial magnetic stimulation (rTMS) for treatment-
resistant major depression (TRMD) in Veterans offers unique clinical trial challenges. Here …

Objectives: Repetitive transcranial magnetic stimulation (rTMS) is increasingly being utilised
as a treatment option for depression, and with this comes a need for a practical review of …

Background The clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) in
treatment resistant patients (at least 4 medication trials) appears to be well accepted and …